Dupilumab in Atopic Dermatitis Linked to Reduced Irritable Bowel Syndrome Risk: A Real-World Cohort Study

Authors

Jasmine Levine, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Rahib K. Islam, LSU Health Sciences Center - New OrleansFollow
Lillian Mo, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Brian S. Kim, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Jordan Talia, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Shari R. Lipner, Department of Dermatology, Weill Cornell Medicine, New York, New York, USA.
Benjamin Ungar, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Document Type

Letter to the Editor

Publication Date

6-25-2025

Publication Title

Allergy

PubMed ID

40560741

Recommended Citation

Levine, Jasmine; Islam, Rahib K.; Mo, Lillian; Kim, Brian S.; Talia, Jordan; Lipner, Shari R.; and Ungar, Benjamin, "Dupilumab in Atopic Dermatitis Linked to Reduced Irritable Bowel Syndrome Risk: A Real-World Cohort Study" (2025). School of Medicine Faculty Publications. 3906.
https://digitalscholar.lsuhsc.edu/som_facpubs/3906
10.1111/all.16637